Education
About Us
Working with TipRanks
Follow Us
Praxis Precision Medicines (PRAX)
NASDAQ:PRAX
Top Page
Praxis Precision Medicines
(NASDAQ:PRAX)
Select Model
Select Model
Rating:67Neutral
Price Target:
$324.00
▲(8.61% Upside)
Action:ReiteratedDate:02/20/26
The score is supported most by strong technical momentum and a positive earnings-call setup (NDA filings, Breakthrough designation, multiple near-term catalysts, and an extended cash runway). These are tempered by weak underlying financial performance (no revenue in 2025, widening losses, and significant cash burn) and limited valuation support due to negative earnings and no dividend.
Positive Factors
Balance sheet strength
Very low debt and materially higher equity/assets improve solvency and strategic optionality. This durable capital structure reduces bankruptcy risk, supports multi-year clinical/commercial programs, and gives management flexibility on timing and partnerships without forcing near-term dilutive financing.
Pro forma cash runway
A pro forma cash balance near $1.5B materially lengthens the runway for late‑stage development and two planned commercial launches. It lowers near‑term refinancing risk, enables hiring and inventory build for launch, and gives time to realize clinical readouts without immediate capital pressure.
Clinical and regulatory progress
Multiple positive Phase III readouts, two NDAs and Breakthrough designation increase approval probability and can accelerate review. These structural regulatory advances enhance competitive positioning, support earlier commercialization planning, and create durable value drivers beyond short‑term market moves.
Negative Factors
High cash burn and losses
Large recurring losses and negative operating cash flow are structural for a development‑stage biotech and steadily deplete resources absent approvals or financing. Sustained burn increases reliance on capital markets or commercial milestones and raises execution risk if timelines slip.
Rising operating and commercialization spend
A marked jump in R&D and G&A plus a planned step‑up for launches creates durable pressure on margins and cash even with recent financings. Higher fixed commercial costs increase the break‑even threshold and magnify downside if launches, label decisions, or payer uptake are delayed.
Payer/access and label uncertainty
Regulatory approval alone may not secure revenue: IRA timing, Medicare Part D dynamics and unresolved label/titration details can materially constrain pricing, coverage and uptake. These structural reimbursement risks can compress peak sales and extend time to revenue realization.
Praxis Precision Medicines (PRAX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$8.31B
Dividend YieldN/A
Average Volume (3M)397.08K
Price to Earnings (P/E)―
Beta (1Y)2.11
Revenue Growth364.98%
EPS Growth-25.33%
CountryUS
Employees116
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-3.50
Shares Outstanding27,850,834
10 Day Avg. Volume429,724
30 Day Avg. Volume397,077
Financial Highlights & Ratios
PEG Ratio-0.68
Price to Book (P/B)7.55
Price to Sales (P/S)0.00
P/FCF Ratio-26.63
Enterprise Value/Market Cap0.72
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-31.37
Enterprise Value/Ebitda-18.98
Forecast
1Y Price Target
$603.80Price Target Upside102.41% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering15
EPS Forecast (FY)-15.3
Revenue Forecast (FY)$6.38M
Praxis Precision Medicines Business Overview & Revenue Model
Company DescriptionPraxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremor. The company is also developing PRAX-562, a persistent sodium current blocker that is in Phase I clinical trial to treat severe pediatric epilepsy and adult cephalgia; PRAX-222, an antisense oligonucleotide (ASO) for patients with gain-of-function (GOF) SCN2A epilepsy; and KCNT1 program for the treatment of KCNT1 GOF epilepsy. It has a cooperation and license agreement with RogCon Inc.; a license agreement with Purdue Neuroscience Company; a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.
How the Company Makes Moneynull
Praxis Precision Medicines Earnings Call Summary
Earnings Call Date:Feb 19, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 13, 2026
Earnings Call Sentiment Positive
The call emphasized major clinical and regulatory progress (two NDAs filed, positive Phase III results, Breakthrough Therapy designation, multiple near-term readouts) and a strengthened balance sheet (pro forma ~$1.5B) enabling commercialization. Offsetting this are materially higher operating expenses (full-year OpEx +56% y/y), an anticipated further increase in 2026 to support launches, and commercial/payer timing uncertainties (including IRA considerations and label/titration questions). Overall, the highlights — substantial clinical validation, regulatory progress, clear launch planning, and strong cash runway — outweigh the lowlights related to cost increases and access timing risk.Q4-2025 Updates
Positive Updates
Two NDA Submissions
Praxis submitted two NDAs in early 2026: ulixacaltamide for essential tremor and relutrigine for SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs). Both submissions follow positive clinical readouts and productive FDA interactions.
Positive Phase III / Clinical Readouts
Ulixacaltamide (Essential3) met primary and key secondary endpoints with clinically meaningful benefit and received FDA Breakthrough Therapy designation in December. Relutrigine delivered statistically significant, rapid and durable efficacy in EMBOLD (SCN2A/SCN8A). Vormatrigine RADIANT Phase III showed 58% of patients achieving ≥50% seizure reduction at week 1 and 100% median weekly seizure reduction in OLE at week 9 (sustained to week 16).
Multiple Near-Term Catalysts
Upcoming readouts and milestones include: POWER1 topline for vormatrigine in focal epilepsy expected in Q2 2026, elsunersen EMBRAVE Part A topline from original nine patients expected H1 2026, completion of POWER2 enrollment by end of 2026, EMBRAVE3 enrollment completion and potential NDA for elsunersen later in 2026, and EMERALD enrollment completion (relutrigine broader DEE) in 2026 with potential sNDA by 2027.
Strong Balance Sheet and Cash Runway
Praxis ended Q4 2025 with $926 million in cash, equivalents and marketable securities versus $469 million at 12/31/2024 (increase of $457 million, approximately +97%). Subsequent January 2026 offering raised $621 million, resulting in pro forma cash of ~ $1.5 billion, which management expects will fund operations into 2028.
Commercial Readiness
Company is building commercial infrastructure and inventory for two near-term launches (ulixacaltamide and relutrigine), including key hires, medical education planning (major presence at AAN with ~15 presentations), and prelaunch activities designed to support a U.S. launch.
Large Addressable Markets and Revenue Potential
Management estimates: ulixacaltamide addressable ET population of ~2 million U.S. patients (7+ million with ET overall) with >$10 billion annual potential; relutrigine initial SCN2A/SCN8A U.S. addressable ~10,000 patients with potential expansion to 200,000+ DEE patients and up to ~$5 billion annual potential; vormatrigine addressable ~3 million with ~$4 billion peak potential; elsunersen potential >$1 billion.
Regulatory and Exclusivity Advantages
Relutrigine and elsunersen have Rare Pediatric Disease designation, making them eligible for pediatric review vouchers upon approval, which could add commercial and strategic value.
Negative Updates
Elevated Operating Expenses
Q4 2025 operating expenses totaled $97.0 million vs $71.4 million in Q4 2024 (+$25.6M, ~+35.8%). R&D in Q4 increased to $77.5M from $56.3M (+$21.2M, ~+37.7%) and G&A to $19.5M from $15.1M (+$4.4M, ~+29.1%). Full-year operating expenses were $326M in 2025 vs $209M in 2024 (+$117M, ~+56.1%).
Expectations for Further Spend in 2026
Management expects a significant step-up in spending in 2026 to fund commercial launch activities and ongoing pipeline progression, which will continue to pressure cash flow despite recent financings.
Regulatory Timing and Priority Review Decisions
Praxis chose not to request Priority Review for ulixacaltamide (requested Priority Review for relutrigine). The standard review strategy may delay commercial timing for ulixacaltamide and was partially driven by strategic considerations (e.g., IRA/payer timing), introducing timing uncertainty for launch and reimbursement.
Label and Titration Uncertainty
There is some uncertainty regarding final label language and titration schedules for ulixacaltamide; management proposed alternative titration schedules but the final label will be determined by FDA and remains uncertain at filing.
Payer / Access Risk and IRA Considerations
Management highlighted Medicare Part D / Inflation Reduction Act timing and payer reauthorization dynamics as a key commercial consideration (and part of the reason for the standard review request for ulixacaltamide), indicating potential access and pricing complexity at launch.
Competitive and Execution Risks
Vormatrigine faces a competitive landscape with other late-stage potassium-channel-focused therapies and evolving standards of care; multiple ongoing readouts across the portfolio create execution risk if any pivotal studies fail or are delayed.
Company Guidance
Praxis provided detailed near‑term regulatory, clinical and financial guidance: the company has submitted two NDAs (ulixacaltamide for essential tremor and relutrigine for SCN2A/SCN8A DEEs), expects POWER1 topline results for vormatrigine and EMBRAVE (elsunersen) data next quarter, aims to complete POWER2 enrollment in H2 2026 and EMERALD enrollment this year (targeting an sNDA from EMERALD by 2027), and converted EMBRAVE3 to a single‑arm baseline‑controlled design of ~30 patients with potential NDA next year (with topline data from the original nine‑patient EMBRAVE Part A due in H1). They reiterated key population and peak‑revenue assumptions: >7M people in the U.S. with ET (≈2M addressable) and >$10B peak for ulixacaltamide; ~10k initial U.S. SCN2A/SCN8A patients and >200k broader DEE patients with up to $5B potential for relutrigine; ~3M U.S. common epilepsy patients and >$4B potential for vormatrigine; and >$1B potential for elsunersen — cumulatively >$20B opportunity. Financially, Q4 2025 operating expenses were $97M (R&D $77.5M; G&A $19.5M), full‑year op ex $326M vs $209M in 2024, cash was $926M at year‑end (vs $469M a year earlier) plus $621M raised in January for pro forma cash ≈$1.5B expected to fund operations into 2028, and 2026 spend is expected to rise materially to support commercial launches, prelaunch hires, inventory build and a medical‑education campaign (15 presentations planned at AAN in April).Praxis Precision Medicines Financial Statement Overview
Summary
Financials reflect a development-stage biotech profile: very weak profitability and accelerating losses (2025 net loss ~ $303M; revenue fell to zero), and heavy ongoing cash burn (2025 operating cash flow ~ -$249M). Offsetting this is a strong, low-debt balance sheet with sharply higher equity/assets, reducing near-term solvency risk.Income Statement
Profitability is weak and deteriorating: the company is consistently loss-making with EBIT and net income deeply negative across all annual periods, and losses widened meaningfully in 2025 (net loss of ~$303M vs. ~$183M in 2024). Revenue is very small and volatile, dropping to zero in 2025 after ~$8.6M in 2024, which limits operating leverage and makes margins uninformative/unstable. The main positive is that the business has been able to generate some revenue in recent years (2023–2024), but the overall trajectory shows heavy R&D/operating spend with no clear path to near-term profitability in the provided data.18
Very Negative
Balance Sheet
Balance sheet leverage is very low, with total debt near-zero relative to equity (debt-to-equity ~0.0001 in 2025 and ~0.0031 in 2024), which reduces financial risk and provides flexibility. Equity and assets increased sharply in 2025 (equity ~$878M vs. ~$445M in 2024; assets ~$938M vs. ~$483M), suggesting improved capitalization. The key weakness is continued value erosion from losses: return on equity remains negative across all years (about -35% in 2025 and -41% in 2024), meaning shareholder capital is being consumed by ongoing operating deficits.64
Positive
Cash Flow
Cash generation is weak: operating cash flow and free cash flow are consistently negative, and cash burn accelerated in 2025 (operating cash flow about -$249M vs. -$132M in 2024). While free cash flow moved modestly in the right direction year-over-year in 2025 (growth ~9%), the absolute level of burn is high. A relative positive is that free cash flow tracks closely with net income (roughly 1x in most years), indicating losses are largely reflected in cash rather than being masked by non-cash accounting—however, that also underscores that the business is consuming cash at a rate similar to reported losses.26
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 8.55M | 2.45M | 0.00 | 0.00 |
| Gross Profit | -140.00K | -143.86M | -84.32M | -154.44M | 0.00 |
| EBITDA | -303.13M | -199.81M | -125.94M | -213.57M | -167.15M |
| Net Income | -303.27M | -182.82M | -123.28M | -214.03M | -167.06M |
Balance Sheet | |||||
| Total Assets | 937.91M | 483.11M | 87.95M | 115.13M | 292.75M |
| Cash, Cash Equivalents and Short-Term Investments | 599.33M | 392.57M | 81.30M | 100.49M | 275.91M |
| Total Debt | 110.00K | 1.37M | 2.50M | 3.50M | 4.31M |
| Total Liabilities | 59.77M | 37.66M | 18.28M | 39.02M | 41.94M |
| Stockholders Equity | 878.14M | 445.45M | 69.67M | 76.11M | 250.81M |
Cash Flow | |||||
| Free Cash Flow | -249.12M | -131.76M | -111.19M | -185.49M | -125.60M |
| Operating Cash Flow | -249.07M | -131.76M | -111.14M | -185.04M | -124.55M |
| Investing Cash Flow | -311.15M | -248.49M | 38.95M | 96.89M | -140.52M |
| Financing Cash Flow | 702.17M | 514.32M | 91.87M | 10.46M | 107.59M |
Praxis Precision Medicines Technical Analysis
Neutral
298.31
Price Trends
312.99
Negative
268.52
Positive
162.91
Positive
Market Momentum
-5.70
Positive
43.62
Neutral
21.87
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PRAX, the sentiment is Neutral. The current price of 298.31 is below the 20-day moving average (MA) of 315.57, below the 50-day MA of 312.99, and above the 200-day MA of 162.91, indicating a neutral trend. The MACD of -5.70 indicates Positive momentum. The RSI at 43.62 is Neutral, neither overbought nor oversold. The STOCH value of 21.87 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for PRAX.
Praxis Precision Medicines Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | $8.31B | -21.87 | -58.74% | ― | 364.98% | -25.33% | |
59 Neutral | $1.09B | -25.24 | -14.83% | ― | 2147.20% | -269.99% | |
54 Neutral | $1.28B | -4.30 | -156.98% | ― | ― | -38.04% | |
53 Neutral | $811.26M | -6.70 | -100.29% | ― | 5459.66% | -59.70% | |
52 Neutral | $468.51M | -7.51 | -28.71% | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $1.03B | ― | -14.16% | ― | 7.16% | 3.95% |
* Healthcare Sector Average
PRAX
Praxis Precision Medicines
298.31
260.60
691.06%
SPRY
ARS Pharmaceuticals
8.17
-4.72
-36.62%
ABCL
AbCellera Biologics
3.40
0.81
31.27%
ZBIO
Zenas BioPharma, Inc.
22.30
12.99
139.53%
UPB
Upstream Bio, Inc.
8.67
0.97
12.60%
SEPN
Septerna, Inc.
24.18
17.81
279.59%
Praxis Precision Medicines Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Praxis Precision Medicines Announces Major Underwritten Equity Offering
Positive
Jan 7, 2026
On January 6, 2026, Praxis Precision Medicines entered into an underwriting agreement with a syndicate of banks for an underwritten public offering of 2,212,000 shares of common stock at $260 per share, with closing expected on January 8, 2026, and the underwriters fully exercising their option on January 7, 2026, to purchase an additional 331,800 shares. The company expects to raise approximately $621.2 million in net proceeds, which it plans to use, together with existing cash, equivalents and marketable securities, to fund commercialization preparation for late-stage candidates, continue clinical and early-stage R&D, and cover working capital and general corporate needs, and believes this capital should support its operating and capital expenditure requirements into 2028, potentially strengthening its financial position and funding visibility for stakeholders.
The most recent analyst rating on (PRAX) stock is a Buy with a $843.00 price target. To see the full list of analyst forecasts on Praxis Precision Medicines stock, see the PRAX Stock Forecast page.
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Praxis Wins FDA Breakthrough Status for Ulixacaltamide
Positive
Dec 29, 2025
On December 29, 2025, Praxis Precision Medicines, Inc. reported that the U.S. Food and Drug Administration granted Breakthrough Therapy Designation to its investigational drug ulixacaltamide for the treatment of patients with essential tremor, a serious movement disorder. The designation, which is intended to speed development and regulatory review of promising therapies, was awarded on the strength of positive topline results from the company’s Essential3 program, comprising two pivotal Phase 3 studies, and marks a significant regulatory milestone that could accelerate ulixacaltamide’s path to market and potentially enhance Praxis’s competitive position in the neurology space.
The most recent analyst rating on (PRAX) stock is a Buy with a $843.00 price target. To see the full list of analyst forecasts on Praxis Precision Medicines stock, see the PRAX Stock Forecast page.
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.